Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.49 |
| ▸ | FPR3 | P25089 | 5/20 | 0.37 |
| ▸ | FPR2 | P25090 | 5/20 | 0.37 |
| ▸ | PHF13 | Q86YI8 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147083 | 0.99 | MC4R (0.48) | MC4RFPR3FPR2PHF13L3MBTL3 | |
| SCHEMBL13147330 | 0.98 | MC4R (0.49) | MC4RFPR3FPR2PHF13L3MBTL3 | |
| SCHEMBL13147119 | 0.91 | ALDH1A1 (0.45) | MC4RL3MBTL1KMT2A | |
| SCHEMBL13147146 | 0.90 | MC4R (0.40) | MC4RFPR3FPR2PHF13L3MBTL3 | |
| SCHEMBL13147357 | 0.90 | MC4R (0.45) | MC4R | |
| SCHEMBL14193791 | 0.82 | MC4R (0.72) | MC4R | |
| SCHEMBL13147367 | 0.81 | MC4R (0.73) | MC4R | |
| SCHEMBL13147213 | 0.80 | MC4R (0.43) | MC4RHTR3A | |
| SCHEMBL3090271 | 0.79 | MC4R (0.72) | MC4R | |
| SCHEMBL13147205 | 0.78 | MC4R (0.48) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | MC4R 1/4885FPR3 307/4885FPR2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.